The word remission as applied to type 2 diabetes is still unfamiliar to many patients and, truthfully, to many clinicians. This is in part because the condition has been framed for decades as chronic and progressive: a one-way deterioration managed by progressively more intensive medication. This framing has shaped clinical protocols, patient expectations, and the design of healthcare systems. It is also, in important respects, wrong. A growing body of evidence, culminating in randomised controlled trials published in the most prestigious medical journals, establishes that type 2 diabetes diagnosed within approximately ten years can be reversed in a substantial proportion of cases through intensive lifestyle intervention, with the biological definition of remission, HbA1c below 48 millimoles per mole without diabetes medication for at least three months, achieved and maintained for years.
Understanding Why Type 2 Diabetes Is Reversible
Type 2 diabetes is not primarily a disease of the pancreas. It is primarily a disease of ectopic fat deposition, specifically the accumulation of fat in the liver and pancreas in quantities that impair the function of each. Roy Taylor at Newcastle University, whose work has been foundational in establishing the reversibility of type 2 diabetes, developed the twin cycle hypothesis: hepatic insulin resistance, driven by liver fat accumulation from caloric excess, leads to elevated fasting glucose and compensatory hyperinsulinaemia; the chronic hyperinsulinaemia then drives fat accumulation in the pancreas, impairing the beta cells that produce insulin; the combination of liver insulin resistance and impaired insulin secretion produces the clinical picture of type 2 diabetes. Critically, both ectopic fat deposits can be removed through caloric deficit, restoring normal hepatic insulin sensitivity and pancreatic beta-cell function.
Taylor's research, initially in small proof-of-concept studies and then in the DiRECT trial, demonstrated that a low-calorie diet producing 15 kilograms of weight loss reversed liver and pancreatic fat accumulation in MRI studies and was associated with type 2 diabetes remission in 86 percent of participants achieving that weight loss at one year. The critical finding was that pancreatic beta-cell function, previously assumed to be permanently impaired in established type 2 diabetes, recovered when the ectopic fat burden was removed, even in individuals who had been diabetic for six years. Beta cells are not dead in early-stage type 2 diabetes; they are suppressed by ectopic fat deposition and can recover.
The DiRECT Trial and Its Real-World Implications
The DiRECT trial, published in The Lancet in 2018 and with five-year follow-up data published in 2022, enrolled 298 adults with type 2 diabetes diagnosed within six years, randomised to either standard care or a structured weight management programme within primary care. The intervention consisted of a total diet replacement low-calorie formula providing 825 to 853 calories per day for twelve to twenty weeks, followed by a structured food reintroduction phase, and then long-term support for weight maintenance. At one year, 46 percent of the intervention group achieved remission. At two years, 36 percent remained in remission. At five years, 13 percent of the original intervention group remained in sustained remission, defined as HbA1c below 48 mmol/mol without medication for the full five years.
The five-year figure requires context. The primary predictor of sustained remission was sustained weight loss; those who maintained 10 kilograms or more of weight loss at five years had a 53 percent remission rate at that timepoint. The challenge was not that remission was unachievable at five years; it was that weight maintenance for five years after a low-calorie diet period proved difficult for the majority without intensive ongoing support. This points to the primary clinical challenge: achieving remission through caloric deficit is straightforward in principle; maintaining the conditions for remission over years requires structured, ongoing support that the NHS in its current form is not consistently able to provide.
Exercise as an Independent Remission Pathway
Weight loss is not the only pathway to type 2 diabetes remission. Exercise can improve glycaemic control and, in some cases, produce remission through mechanisms that are partly independent of weight change. A 2016 randomised controlled trial published in Diabetologia found that a 24-week structured aerobic and resistance exercise programme produced HbA1c reductions of 1.2 to 1.5 percent in adults with type 2 diabetes, comparable to the effect of adding a second antidiabetic drug. The mechanisms include increased GLUT4 expression in muscle from resistance training, which allows insulin-independent glucose uptake; improved hepatic insulin sensitivity from visceral fat reduction; and reduced pancreatic fat from the caloric deficit component of exercise-induced weight loss.
For adults on the Isle of Man with type 2 diabetes or pre-diabetes attending Zhen Wellness, the clinical approach is to establish the degree of reversibility based on duration of diagnosis, current HbA1c, current pancreatic function estimated from fasting C-peptide, and the degree of ectopic fat accumulation estimated from body composition analysis and liver enzyme measurement. The programme combines a structured caloric reduction approach with progressive resistance and aerobic exercise, protein-optimised nutrition, sleep optimisation, and regular monitoring of blood glucose, HbA1c, and body composition. The evidence does not promise remission for every adult with type 2 diabetes; it does promise that a significant proportion of those with recent-onset disease, approached with appropriate intensity, can achieve it.
- Type 2 diabetes is primarily caused by ectopic fat in the liver and pancreas suppressing insulin signalling and secretion, not irreversible beta-cell death
- 86 percent of DiRECT trial participants achieving 15 kg weight loss achieved remission at 1 year
- 36 percent remained in remission at 2 years; 53 percent of those maintaining 10 kg loss at 5 years remained in remission
- Pancreatic beta-cell function recovers when ectopic fat is removed, even after 6 years of diagnosed type 2 diabetes
- Exercise combined with dietary change produces HbA1c reductions of 1.2 to 1.5 percent, equivalent to adding a second antidiabetic drug
- Resistance training increases GLUT4 expression in muscle, allowing insulin-independent glucose disposal
- Duration of diagnosis, fasting C-peptide, and body composition are the key variables in assessing reversibility
Sources
- Lean, M.E.J., et al. (2018). Primary care-led weight management for remission of type 2 diabetes. Lancet, 391(10120), 541-551.
- Taylor, R., et al. (2022). Remission of type 2 diabetes: an update from the DiRECT randomised controlled trial at 5 years. The Lancet Diabetes & Endocrinology, 10(11), 793-802.
- Taylor, R. (2013). Type 2 diabetes: etiology and reversibility. Diabetes Care, 36(4), 1047-1055.
- Church, T.S., et al. (2010). Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes. JAMA, 304(20), 2253-2262.
- Cuthbertson, D.J., et al. (2016). Altered dietary energy intake induces remission of insulin resistance in obese individuals. Diabetologia, 59(6), 1255-1263.